| (Values in U.S. Thousands) | Jun, 2024 | Mar, 2024 | Dec, 2023 | Sep, 2023 | Jun, 2023 |
| Sales | 5,580 | 5,720 | 3,620 | 6,660 | 5,500 |
| Sales Growth | -2.45% | +58.01% | -45.65% | +21.09% | +44.36% |
| Net Income | -11,870 | 1,280 | -4,470 | -800 | -3,810 |
| Net Income Growth | -1,027.34% | +128.64% | -458.75% | +79.00% | +29.31% |
Agile Therapeutics Inc (AGRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey.
Fiscal Year End Date: 12/31